

# Molecular Neurobiology

## Melatonin prevents the harmful effects of obesity on the brain, including at the behavioral level

--Manuscript Draft--

<b>Manuscript Number:</b>	MOLN-D-17-00610R1
<b>Article Type:</b>	Original Article
<b>Keywords:</b>	leptin deficiency, obesity, brain, brain damage, melatonin, aggresome
<b>Corresponding Author:</b>	Adrian Rubio-González Universidad de Oviedo SPAIN
<b>First Author:</b>	Adrian Rubio-González
<b>Order of Authors:</b>	Adrian Rubio-González Juan Carlos Bermejo-Millo Beatriz de Luxán-Delgado Yaiza Potes Zulema Pérez-Martínez José Antonio Boga Ignacio Vega-Naredo Beatriz Caballero Juan José Solano Ana Coto-Montes
<b>Abstract:</b>	<p>Obesity is a health problem caused by a diet rich in energy and the sedentary lifestyle of modern societies. A leptin deficiency is one of the worst causes of obesity, since it results in morbid obesity, a chronic disease without a cure. Leptin is an adipokine secreted in a manner dependent on the circadian rhythm that ultimately reduces food intake. We studied cellular alterations in brain of leptin-deficient obese animals and tested whether these alterations are reflected in abnormal behaviors. Obesity induced increases in oxidative stress and the unfolded protein response caused by endoplasmic reticulum stress. However, the subsequent signaling cascade was disrupted, blocking possible systemic improvements and increasing the production of misfolded proteins, that trigger autophagy. Up-regulated autophagy was not indefinitely maintained and misfolded proteins accumulated in obese animals, which led to aggresome formation. Finally, neurodegenerative markers together with anxiety and stress-induced behaviors were observed in leptin-deficient mice. As oxidative stress has an essential role in the development of these harmful effects of obesity, melatonin, a powerful antioxidant, might counteract these effects on the brain. Following treatment with melatonin, the animals' antioxidant defenses were improved and misfolded protein, proteasome activity and autophagy decreased. Aggresome formation was reduced due to the reduction in the levels of misfolded proteins and the reduction in tubulin expression, a key element in aggresome development. The levels of neurodegenerative markers were reduced and the behaviors recovered. The data support the use of melatonin in therapeutic interventions to reduce brain damage induced by leptin deficiency-dependent obesity.</p>

1       **MELATONIN PREVENTS THE HARMFUL EFFECTS OF OBESITY**  
2       **ON THE BRAIN, INCLUDING AT THE BEHAVIORAL LEVEL**

3  
4       Adrian Rubio-González <sup>1a</sup>, Juan Carlos Bermejo-Millo <sup>1a</sup>, Beatriz de Luxán-Delgado <sup>1a</sup>, Yaiza Potes <sup>1a</sup>,  
5       Zulema Pérez-Martínez <sup>2a</sup>, José Antonio Boga <sup>2a</sup>, Ignacio Vega-Naredo <sup>1a</sup>, Beatriz Caballero <sup>1a</sup>, Juan  
6       José Solano <sup>3a</sup>, Ana Coto-Montes <sup>1a\*</sup>

7  
8       <sup>1</sup>Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, Avda. Julián  
9       Clavería s/n, 33006, Oviedo, Principado de Asturias, Spain.

10       <sup>2</sup>Microbiology Service, Hospital Universitario Central de Asturias, Avda. Roma, s/n, 33011, Oviedo,  
11       Principado de Asturias, Spain.

12       <sup>3</sup>Geriatrics Service, Hospital Monte Naranco, Avda. Doctores Fernández Vega, 107, 33012, Oviedo,  
13       Principado de Asturias, Spain.

14       <sup>a</sup>Members of Research Team cROS (cellular Response to Oxidative Stress).

15  
16       **\*Corresponding author**

17       Ana Coto Montes

18       Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, Avda. Julián  
19       Clavería, s/n, 33006, Oviedo, Principado de Asturias, Spain

20       Phone:

21       Fax:

22       E-mail:

23  
24       **Keywords**

25       leptin deficiency, obesity, brain, brain damage, melatonin, aggressive.

26

27 **Abstract**

28 Obesity is a health problem caused by a diet rich in energy and the sedentary lifestyle of modern  
29 societies. A leptin deficiency is one of the worst causes of obesity, since it results in morbid obesity, a  
30 chronic disease without a cure. Leptin is an adipokine secreted in a manner dependent on the circadian  
31 rhythm that ultimately reduces food intake. We studied cellular alterations in brain of leptin-deficient  
32 obese animals and tested whether these alterations are reflected in abnormal behaviors. Obesity induced  
33 increases in oxidative stress and the unfolded protein response caused by endoplasmic reticulum stress.  
34 However, the subsequent signaling cascade was disrupted, blocking possible systemic improvements  
35 and increasing the production of misfolded proteins, that trigger autophagy. Up-regulated autophagy  
36 was not indefinitely maintained and misfolded proteins accumulated in obese animals, which led to  
37 aggresome formation. Finally, neurodegenerative markers together with anxiety and stress-induced  
38 behaviors were observed in leptin-deficient mice. As oxidative stress has an essential role in the  
39 development of these harmful effects of obesity, melatonin, a powerful antioxidant, might counteract  
40 these effects on the brain. Following treatment with melatonin, the animals' antioxidant defenses were  
41 improved and misfolded protein, proteasome activity and autophagy decreased. Aggresome formation  
42 was reduced due to the reduction in the levels of misfolded proteins and the reduction in tubulin  
43 expression, a key element in aggresome development. The levels of neurodegenerative markers were  
44 reduced and the behaviors recovered. The data support the use of melatonin in therapeutic interventions  
45 to reduce brain damage induced by leptin deficiency-dependent obesity.

46

## 47 **Introduction**

48 The prevalence of the overweight and obesity epidemics have significantly increased in the last three  
49 decades, including a dramatic rise in the prevalence of both disorders among adolescents. Currently,  
50 39% of the global population is overweight and 13% is obese [1]. Overweight and obesity are the fifth  
51 leading causes of death worldwide; therefore, obesity and its associated health problems urgently require  
52 new strategies for effective treatments.

53 Obesity is a risk factor for many diseases such as diabetes, musculoskeletal disorders, some cancers,  
54 renal pathologies and, primarily cardiovascular diseases [2]. In addition, central nervous system damage  
55 induced by obesity has recently been reported [3,4]. According to animal studies, high-energy diet  
56 damages the structure and function of the hippocampus [5]. The brain is particularly susceptible to  
57 oxidative stress due to its high glucose and oxygen consumption [6], which generates a large amount of  
58 reactive oxygen species (ROS), and its poor antioxidant defense system [7].

59 Oxidative stress damages macromolecules and ultimately leads to dysfunctional neurons. Thus, cells  
60 (particularly postmitotic cells such as neurons) contain quality control mechanisms such as the unfolded  
61 protein response (UPR), proteasome and autophagy to remove damaged proteins [8]. When  
62 unfolded/misfolded proteins accumulate in the endoplasmic reticulum (ER), ER stress occurs and  
63 induces the UPR in order to decrease protein synthesis and increase the synthesis of chaperones and the  
64 activity of the ubiquitin/proteasome system [9,10]. If this response is not able to repair or avoid the  
65 accumulation of unfolded/misfolded proteins, the proteasome [11] and autophagy, particularly  
66 chaperone-mediated autophagy (CMA) and macroautophagy [12], are responsible for removing these  
67 proteins. Unfortunately, if these mechanisms fail, aggresomes begin to accumulate, hampering vesicle  
68 traffic. As shown in a recent publication by our group, autophagy is altered in the livers of obese  
69 individuals [13].

70 Obesity is caused by several factors, physiological to psychological conditions, and some unknown  
71 factors. However, leptin is one of the main factors, as a reduction in its levels or receptor inefficiency  
72 leads to morbid obesity [14,15].

73 Leptin, a 16 kDa adipokine, is an anorexigenic peptide hormone synthesized in and secreted from  
74 peripheral adipocytes. Upon binding to its receptor within the hypothalamus, leptin induces a  
75 biochemical cascade that ultimately reduces food intake and increases energy expenditure. This peptide  
76 is secreted with circadian rhythmicity, with maximal production in the middle of the night [16]; thus,  
77 leptin is inevitably associated with melatonin.

78 Melatonin (N-acetyl-5-methoxytryptamine) is synthesized by the pineal gland and plays a fundamental  
79 role in the control of circadian rhythms [17]. In fact, its relation with leptin has been established.  
80 According to several studies, melatonin administration decreases plasma and serum leptin levels in rats  
81 [18-20]. Moreover, pinealectomy results in an increase in circulating leptin concentrations, whereas the  
82 circadian rhythm of leptin secretion remains unchanged [21]. In summary, melatonin administration  
83 reduces serum leptin concentrations in both pinealectomized and normal rats.

84 Melatonin has many other functions in addition to its Zeitgeber role. Melatonin is one of the best known  
85 natural antioxidants [22,23]. The high efficiency of melatonin as an antioxidant depends on its ability to  
86 easily cross cell membranes due to its amphipathic nature [12]. Melatonin is also implicated in changes  
87 in body weight, depending on the photoperiod [24]. This molecule promotes weight loss by stimulating  
88 non-shivering thermogenesis and the recruitment of brown fat in small mammals [25]. In addition,  
89 melatonin regulates many other aspects of body weight and adiposity, such as energy intake and  
90 expenditure, glucose uptake [26], the serum lipid profile, blood pressure and inflammation [27].  
91 Numerous publications have confirmed the regulatory roles of melatonin in the cell cycle, apoptosis and  
92 autophagy [12,17,28]. These effects of melatonin have been poorly studied in relation to its influence  
93 on actions of leptin in the brain.

94 Based on these considerations, the present study thoroughly analyzes the neuronal and behavioral  
95 alterations in leptin-deficient mice and whether a melatonin treatment counteracts the negative effects.  
96 Leptin deficiency-induced obesity caused diverse forms of cellular damage and led to abnormal  
97 behaviors through a similar pathway to aging, which was partially prevented by the melatonin treatment.

98

## 99 **Materials and methods**

## 100 **Animals**

101 Sixteen six-week-old male wild-type mice (C57BL/6J) and sixteen six-week-old male leptin-deficient  
102 obese B6.V-Lepob/J (ob/ob) mice were purchased from Charles River Laboratories (Barcelona, Spain).  
103 The ob/ob mice are characterized by hyperphagia, massive obesity (these mice weigh up to four times  
104 more than wild-type mice), transient hyperglycemia, and elevated plasma insulin concentrations (10-50  
105 times higher than normal) [29]. This syndrome is inherited as a single autosomal recessive gene located  
106 on chromosome 6 [29]. The mice were housed two per cage under a 12:12 hour dark:light cycle at 22 ±  
107 2 °C. The animals received tap water and a standard chow diet *ad libitum*. Higher food intake and the  
108 subsequent increase in the body mass index of the ob/ob mice compared with wild-type animals were  
109 reported previously [13].

110

## 111 **Body and tissue parameters**

112 All of the animals were weighed at the beginning (baseline) and end of the experiment (sacrifice) and  
113 both brain and body weights were recorded.

114

## 115 **Melatonin treatment**

116 After a two-week acclimatization period, animals were randomly divided into four groups with eight  
117 mice per group: the untreated control groups of wild-type and ob/ob mice (WC and ObC, respectively)  
118 and the melatonin-treated groups of wild-type and ob/ob mice (WM and ObM, respectively).

119 Two hours after the lights were switched off, melatonin (Sigma-Aldrich, St. Louis, MO, USA) was  
120 intraperitoneally injected at a dose of 500 µg/kg body weight daily for 4 weeks. Melatonin was dissolved  
121 in 0.5% absolute ethanol:saline. Animals in the control groups received a comparable dose of vehicle  
122 via the same route for the same treatment duration.

123 The animals were euthanized by decapitation, and the brain of each mouse was immediately removed,  
124 flash-frozen in liquid nitrogen and stored at -80 °C until further analysis. The experimental protocol was  
125 approved by the Oviedo University Animal Care and Use Committee. All experiments were performed

126 according to the Spanish Government Guide and the European Community Guide for Animal Care  
127 (Council Directive 86/609/EEC).

128

### 129 **Tissue processing**

130 The brain of each mouse was homogenized in buffer (pH 7.5) containing 50 mM sodium phosphate  
131 buffer, 100 mM NaCl, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM NaF and 1% Triton at a ratio 1:10 (w:v) using an Ultra-  
132 Turrax T25 Mixer (IKA, Staufen, Germany). The homogenates were centrifuged at 900 g for 6 minutes  
133 at 4 °C. Supernatants containing proteins were collected, aliquoted and frozen at -80 °C until further  
134 analysis.

135

### 136 **Protein quantification**

137 The Bradford method was used to quantify the protein concentrations in the brain homogenates [30].

138

### 139 **Oxidative damage**

#### 140 *Protein oxidative damage*

141 Protein oxidative damage was determined by measuring the concentrations of carbonylated proteins  
142 using the methods described by Levine *et al.* [31], with the modifications reported by Coto-Montes and  
143 Hardeland [32]. The results are presented as nmol carbonylated protein/mg protein.

144

### 145 **Antioxidant enzyme activities**

#### 146 *Total antioxidant activity*

147 Total antioxidant activity (TAA) was determined using the 2,2'-azino-bis(3-ethylbenzothiazoline-6-  
148 sulphonic acid) (ABTS) cation radical method [33,34]. The results are expressed as mg equivalents  
149 Trolox/mg protein.

150

#### 151 *Superoxide dismutase activity*

152 Superoxide dismutase (SOD; EC 1.15.1.1) activity was measured using the method reported by Martin  
153 *et al.* [35]. This enzyme inhibits hematoxylin auto-oxidation to the colored compound hematein. The  
154 results are expressed as SOD units/mg protein.

155

#### 156 *Catalase activity*

157 Catalase (CAT; EC 1.11.1.6) activity was assayed using the method reported by Lubinsky and Bewley  
158 [36] and H<sub>2</sub>O<sub>2</sub> as the substrate. The results are expressed as  $\mu\text{mol H}_2\text{O}_2/\text{mg protein}\cdot\text{minute}$ .

159

#### 160 *Glutathione peroxidase activity*

161 Glutathione peroxidase (GPx; EC 1.11.1.9) catalyzes the reduction of H<sub>2</sub>O<sub>2</sub> to H<sub>2</sub>O using the reducing  
162 agent reduced glutathione (GSH), which is oxidized to glutathione (GSSG). The assay was performed  
163 by monitoring the oxidation of NADPH [37]. The results are expressed as  $\mu\text{mol NADPH}/\text{mg}$   
164  $\text{protein}\cdot\text{minute}$ .

165

#### 166 *Glutathione reductase activity*

167 Glutathione reductase (GR; EC 1.6.4.2) activity was measured using the method described by Goldberg  
168 and Spooner [38]. This enzyme catalyzes the reduction of oxidized glutathione (GSSG) to reduced  
169 glutathione (GSH) using NADPH + H<sup>+</sup> as the substrate. The assay was performed by monitoring the  
170 oxidation of NADPH [37]. The results are expressed as  $\mu\text{mol NADPH}/\text{mg protein}\cdot\text{minute}$ .

171

### 172 **Enzyme-linked immunosorbent assay (ELISA)**

#### 173 *Tumor necrosis factor $\alpha$ (TNF- $\alpha$ )*

174 Brain levels of TNF- $\alpha$  were determined using a commercially available ELISA kit (KMC3011,  
175 Invitrogen, Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). The assay was  
176 performed according to the manufacturer's instructions, and the results are expressed as pg TNF- $\alpha$ /mg  
177 protein.

178



179 *Interleukin 6 (IL-6)*

180 Brain levels of IL-6 were determined using a commercially available ELISA kit (KMC0061, Novex,  
181 Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). The assay was performed according  
182 to the manufacturer's instructions. The results are expressed as pg IL-6/mg protein.

183

184 **20S proteasome activity**

185 The activity of the 20S proteasome was assessed using a 20S proteasome activity assay kit (APT280,  
186 Chemicon, Merck Millipore, Billerica, MA, USA) based on the detection of the fluorophore 7-amino-  
187 4-methylcoumarin (AMC) after its cleavage from the labeled substrate LLVY-AMC by the  
188 chymotrypsin-like activity of the proteasome. Free AMC was detected by fluorometric quantification  
189 (380/460 nm). The results are presented as  $\mu$ M AMC/mg protein.

190

191 **Western blot immunoassay**

192 Tissue homogenates (50  $\mu$ g of protein per sample) were mixed with Laemmli sample buffer (Bio-Rad  
193 Laboratories, Inc., Hercules, CA, USA) and denatured by boiling at 100°C for 5 minutes. The samples  
194 were fractionated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) at 200  
195 V and subsequently transferred onto a polyvinylidene fluoride (PVDF) membranes (Immobilon TM-P;  
196 Millipore Corp., Bedford, MA, USA) at 350 mA.

197 The membranes were blocked with 5 or 10% (w/v) nonfat dry milk dissolved in Tris-buffered saline  
198 (TBS) (50 mm Tris-HCl, pH 7.5, 150 mm NaCl) for 1 hour at room temperature. Subsequently, the  
199 membranes were incubated with the following primary antibodies overnight at 4°C: anti-IRE1 $\alpha$  (3294,  
200 Cell Signaling Technology, Inc., Danvers, MA, USA), anti-phosphorylated-eIF2 $\alpha$  (3398, Cell Signaling  
201 Technology, Inc., Danvers, MA, USA), anti-ATF-6 $\alpha$  (sc-22799, Santa Cruz Biotechnology, Santa Cruz,  
202 CA, USA), anti-ubiquitin (3933, Cell Signaling Technology, Inc., Danvers, MA, USA), anti-LAMP2A  
203 (ab18528, Abcam, Cambridge, UK), anti-Beclin-1 (sc-10086, Santa Cruz Biotechnology, Santa Cruz,  
204 CA, USA), anti-LC3 (PD014, Medical & Biological Laboratories CO., LTD., Naka-ku Nagoya, Japan),  
205 anti-p62 (H00008878-M01, Abnova, Walnut, CA, USA), anti- $\beta$ -actin (AC-15, Sigma-Aldrich, St.

206 Louis, MO, USA), anti- $\alpha$ -tubulin (sc-23948, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-  
207 vimentin (5741, Cell Signaling Technology, Inc., Danvers, MA, USA), anti- $\beta$ -amyloid (2454, Cell  
208 Signaling Technology, Inc., Danvers, MA, USA), anti- $\alpha$ -synuclein (2642, Cell Signaling Technology,  
209 Inc., Danvers, MA, USA), anti-Tau p-S<sup>199</sup>, anti-Tau p-T<sup>205</sup>, anti-Tau p-S<sup>396</sup> and anti-Tau p-S<sup>404</sup> (44779G,  
210 Invitrogen, Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). The antibodies were  
211 diluted in TBS buffer containing 1% (w/v) nonfat dry milk and 0.02% sodium azide. After three 10  
212 minutes washes in Tris-buffered saline containing Tween (TBS-T) (50 mm Tris/HCl, pH 7.5, 150 mm  
213 NaCl, and 0.05% Tween-20), the membranes were incubated with the corresponding horseradish  
214 peroxidase-conjugated secondary antibody (anti-goat (A4174, Sigma-Aldrich, St. Louis, MO, USA),  
215 anti-mouse (7076, Cell Signaling Technology, Inc., Danvers, MA, USA), anti-anti-rabbit (7074, Cell  
216 Signaling Technology, Inc., Danvers, MA, USA)) diluted in TBS buffer containing 1% (w/v) nonfat dry  
217 milk for 1 hour at room temperature, followed by three 10 minutes washes in TBS-T.

218 The membranes were developed using a chemiluminescent substrate (WBKLS0500, Merck Millipore,  
219 Billerica, MA, USA) according to the manufacturer's protocol. Protein levels were quantitated using  
220 Image Studio Lite 5.2.5 software (LI-COR Biotechnology, Lincoln, NE, USA). Variations in the levels  
221 of the typical housekeeping proteins (GAPDH,  $\beta$ -actin and  $\alpha$ -tubulin) were found, so Ponceau S staining  
222 was used to ensure equal loading [39]. The results were expressed as percent change from the WC  
223 sample. Due to high LC3-I protein expression and low LC3-II protein expression, LC3-I signal  
224 overexposures covered the low LC3-II signal. Then, we have separately pictures of each protein, since  
225 the problem was always that both proteins needed different exposure times to get the best ones, again  
226 because of low LC3-II protein expression.

227

## 228 **Protein identification by peptide mass fingerprinting**

229 Brain protein homogenates (15  $\mu$ g) were mixed with Laemmli sample buffer (Bio-Rad Laboratories,  
230 Inc., Hercules, CA, USA) and boiled at 100°C for 5 minutes to completely denature the proteins. Both  
231 samples and prestained molecular weight standards (Precision Plus Protein All Blue Standards (Bio-  
232 Rad Laboratories, Inc., Hercules, CA, USA)) were loaded onto 10% SDS-PAGE gels. Gels were  
233 electrophoresed at 100 V, stained with a mixture of 30% (v:v) methanol, 10% (v:v) acetic acid and

234 0.01% (w:v) Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and  
235 destained using a mixture of 40% (v:v) methanol and 10% (v:v) acetic acid. Images of the stained gels  
236 were captured using a GS-800 Imaging Densitometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA)  
237 and semiquantitatively analyzed using Image Studio Lite 5.2.5 software (LI-COR Biotechnology,  
238 Lincoln, NE, USA). The results were expressed as percent change from the WC sample.  
239 The bands of interest were processed according to the protocol described by Oliván *et al.* [40]. Bands  
240 of interest were sent to the proteomics laboratory of Inbiotec S.L. (León, Spain) for identification, where  
241 the proteins were digested according to the method reported by Havlis *et al.* [41] and processed for  
242 further analysis using the method reported by Jami *et al.* [42].  
243 Protein candidates produced by this combined peptide mass fingerprinting/tandem MS search were  
244 considered valid when the global Mascot score was greater than 85 with a significance level of  $p < 0.05$ .

245

#### 246 **Porsolt Swim Test (PST)**

247 The PST developed by Porsolt in 1977 [43] is a model of behavioral hopelessness based on the induction  
248 of immobility in animals in response to a stressful stimulus, and the results are interpreted as the animals'  
249 susceptibility to negative moods.

250 The behavioral test was conducted in a designated behavior room to provide a suitably quiet  
251 environment and the necessary equipment for behavioral assays. The animals were placed in a  
252 transparent glass cylinder (13 cm diameter x 24 cm high), filled with  $22 \pm 2$  °C water. The animals were  
253 subjected to a single-phase test for 4 minutes. Their behaviors were recorded and then designated as  
254 either immobility or mobility. We have considered mobility as vigorous movements with the front  
255 and/or back legs in and out of the water, as proposed by Gersner *et al.* [44]. Passive displacement was  
256 considered as immobility. After each test, the mice were dried with a thermal blanket before being  
257 returned to their accommodation cage.

258

#### 259 **Statistical analysis**

260 All results are presented as the mean values  $\pm$  standard deviations (SD) of the means. All data presented  
261 representative data obtained from at least three separate experiments. The results were analyzed using  
262 two-way analysis of variance (ANOVA), with the first effect analyzing the phenotype (WC and ObC)  
263 and the second effect analyzing the treatment (WC and ObC or WM and ObM), and differences between  
264 individual means were analyzed with the Bonferroni post hoc test. The differences were considered  
265 statistically significant when  $p < 0.05$ . Statistical analyses were performed with GraphPad Prism 6  
266 software (GraphPad Software, Inc., La Jolla, CA, USA).

267

## 268 **Results**

### 269 **Body and tissue parameters**

270 As shown in Table 1, body weight at sacrifice was higher in ob/ob mice than in wild-type mice  
271 ( $p < 0.001$ ); however, the administration of melatonin did not produce changes in this parameter in either  
272 mouse strain. Interestingly, brain weight was significantly lower in ob/ob than in wild-type mice  
273 ( $p < 0.01$ ), and the melatonin treatment slightly increased the brain weight in ob/ob animals to levels  
274 similar to the wild-type mice, although the difference was not significant (Table 1).

275

### 276 **Leptin-deficient mice exhibit greater oxidative damage in the brain**

277 Oxidative damage to proteins was evaluated by measuring the protein carbonyl content and the results  
278 showed greater oxidative damage in brains from leptin-deficient (ob/ob) mice than in brains from wild-  
279 type animals ( $p < 0.05$ ). The melatonin treatment did not alter oxidative protein damage in wild-type  
280 animals, but decreased protein carbonylation in ob/ob mice ( $p < 0.001$ ) (Fig. 1a). We next measured the  
281 levels of the main markers of the first line antioxidant defense system to elucidate the precise mechanism  
282 by which melatonin protected leptin-deficient mice.

283 The ABTS cation radical assay showed similar antioxidant capacities in the brains from both types of  
284 mice. We only detected significant changes after the melatonin treatment, which was able to reduce  
285 TAA levels in both strains ( $p < 0.001$  for WC compared with WM and  $p < 0.01$  for ObC compared with  
286 ObM), probably due to its well-described antioxidant properties (Fig. 1b). We measured the activities

287 of the main antioxidant enzymes to complete the analysis. SOD and CAT activities were also similar in  
288 both types of mice. Melatonin slightly decreased SOD activity, whereas it significantly increased CAT  
289 activity in the brains from wild-type animals ( $p<0.01$ ). Similarly, melatonin significantly decreased SOD  
290 activity and increased CAT activity in leptin-deficient mice ( $p<0.05$  for SOD and  $p<0.001$  for CAT)  
291 (Fig. 1c and d). GPx and GR activities also exhibited a similar pattern. Brains from ob/ob mice showed  
292 increased activities of both antioxidant enzymes compared with brains from wild-type animals ( $p<0.05$   
293 for GPx and  $p<0.01$  for GR). Although the melatonin treatment induced a slight increase in GPx activity  
294 in wild-type animals, this increase was only significant in ob/ob mice ( $p<0.01$ ) (Fig. 1e). In contrast, the  
295 melatonin treatment was only able to significantly increase GR activity in the wild-type mice ( $p<0.01$ )  
296 (Fig. 1f). In summary, the melatonin treatment induced a readjustment in the antioxidant system,  
297 improving the redox balance, particularly in ob/ob animals, by stimulating SOD, CAT and GPx  
298 activities.

299

### 300 **Leptin deficiency-induced obesity alters brain cytokine levels**

301 We measured TNF- $\alpha$  and IL-6 levels to evaluate whether a leptin deficiency alters inflammation status  
302 in the brain. TNF- $\alpha$  levels were lower in ob/ob mice ( $p<0.001$ ) and IL-6 levels were higher in leptin-  
303 deficient ob/ob mice than in wild-type mice ( $p<0.001$ ). The melatonin treatment also exerted different  
304 effects on both strains by reducing TNF- $\alpha$  levels and increasing IL-6 levels in wild-type animals ( $p<0.05$   
305 for TNF- $\alpha$  and  $p<0.001$  for IL-6) and increasing the levels of both cytokines in ob/ob mice ( $p<0.01$  for  
306 TNF- $\alpha$  and  $p<0.001$  for IL-6) (Fig. 2).

307

### 308 **The leptin deficiency increases ER stress**

309 Oxidative stress, inflammation and ER stress are concatenated processes that are usually activated in  
310 cells in response to stress conditions [45]. Under many pathophysiological conditions, the ER stress  
311 response termed the UPR attempts to alleviate protein misfolding and restore an efficient protein-folding  
312 environment. The three signaling pathways of the UPR, inositol-requiring enzyme 1 $\alpha$  (IRE1 $\alpha$ ), double-  
313 stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK), and

314 activating transcription factor-6 $\alpha$  (ATF-6 $\alpha$ ), were assessed to evaluate whether the UPR is activated in  
315 the leptin-deficient mice [46,47]. Thus, the levels of IRE1 $\alpha$ , p-eIF2 $\alpha$  (phosphorylated-eukaryotic  
316 initiation factor 2 $\alpha$ ) and ATF-6 $\alpha$  were measured. The levels of the IRE1 $\alpha$  protein were similar in both  
317 strains of mice. Although the levels of p-eIF2 $\alpha$  were reduced in ob/ob mice ( $p < 0.001$ ), the levels of  
318 ATF-6 $\alpha$  pathway were increased ( $p < 0.01$ ) in these obese individuals. Wild-type mice treated with  
319 melatonin only exhibited an increase in the IRE1 $\alpha$  protein content ( $p < 0.01$ ), which promotes cell  
320 survival by optimizing the functions of the ER and the cell. In contrast, melatonin reduced the expression  
321 of IRE1 $\alpha$  and ATF-6 $\alpha$  in ob/ob mice ( $p < 0.001$  for IRE1 $\alpha$  and  $p < 0.01$  for ATF-6 $\alpha$ ) by decreasing cellular  
322 stress (Fig. 3a). The last cytoprotective branch of the UPR induces the expression of ER chaperones.  
323 Heat shock cognate 71 kDa (hsc70) protein belongs to the hsp70 family, whose main function is to  
324 prevent protein misfolding and aggregation [48]. The ob/ob mice exhibited decreased expression of  
325 hsc70 protein compared with wild-type animals ( $p < 0.001$ ), whereas the melatonin treatment decreased  
326 its expression in both strains of mice ( $p < 0.001$  for WC compared with WM and  $p < 0.001$  for ObC  
327 compared with ObM) (Fig. 3b).

328 Based on our results, the accumulation of unfolded/misfolded proteins in ob/ob mice triggers the UPR,  
329 which is characterized by the activation of ATF-6 $\alpha$ . This increase in the ATF-6 $\alpha$  levels seems to be  
330 required to facilitate tolerance to chronic stress [49]. The observed decrease in the IRE1 $\alpha$ , ATF-6 $\alpha$  and  
331 hsc70 levels induced by melatonin administration suggests an improvement in protein synthesis and  
332 folding.

333

### 334 **Leptin-deficient mice exhibit reduced proteasome activity**

335 As brains from ob/ob mice exhibited an accumulation of unfolded/misfolded and oxidatively damaged  
336 proteins, the cells may exhibit both a failure of the protein synthesis machinery or alterations in the  
337 degradation systems. These proteins should be eliminated by different protein quality control  
338 mechanisms, such as the ubiquitin-proteasome system. Leptin-deficient ob/ob animals showed a lower  
339 level of 20S proteasome activity than wild-type mice ( $p < 0.001$ ) (Fig. 4a) and a subsequent accumulation  
340 of ubiquitinated proteins ( $p < 0.001$ ) (Fig. 4b). Proteasome activity was also reduced by the melatonin  
341 treatment in both strains ( $p < 0.001$ ) (Fig. 4a), but did not alter the amounts of ubiquitinated proteins,

342 compared with the respective untreated group, which may be related to an improvement in protein  
343 synthesis induced by this indolamine (Fig. 4b).

344

### 345 **Leptin-deficient ob/ob mice activate autophagy**

346 The accumulation of altered proteins together with the impairment of the proteasome-ubiquitin system  
347 probably requires the activation of other protein quality control mechanisms to maintain protein  
348 homeostasis in the brains from obese mice. Thus, we studied the autophagic pathways by measuring the  
349 levels of lysosome-associated membrane protein type 2A (LAMP2A), a marker for CMA, and Beclin-  
350 1, microtubule-associated protein 1 light chain 3 (LC3) and the p62 protein, markers of macroautophagy.  
351 Leptin-deficient mice showed increased LAMP2A expression compared with wild-type animals  
352 ( $p<0.01$ ) and the melatonin treatment reduced its expression ( $p<0.01$ ) to the levels detected in wild-type  
353 animal (Fig. 5). Although ob/ob mice present impaired proteasome activity, CMA is triggered in an  
354 attempt to remove the damaged and unfolded/misfolded proteins.

355 Beclin-1, which plays an essential role in initiating autophagy [50], was expressed at higher levels in  
356 immunoblots of the brains from ob/ob mice than in the brains from wild-type animals ( $p<0.001$ ) (Fig.  
357 5). The most frequently used autophagy marker is LC3, whose lipidated form, known as LC3-II, is  
358 attached to the autophagosome membrane. Consistent with Beclin-1 results, the LC3-I and LC3-II  
359 proteins were expressed at higher levels in ob/ob mice than in wild-type animals ( $p<0.05$  for LC3-I and  
360  $p<0.01$  for LC3-II), indicating that autophagosomes were formed in this leptin-deficient strain (Fig. 5).

361 In addition, the melatonin treatment decreased the levels of all these autophagic biomarkers ( $p<0.001$   
362 for Beclin-1,  $p<0.01$  for LC3-I and  $p<0.001$  for LC3-II), suggesting that melatonin prevents the causes  
363 that trigger the Beclin-1-dependent autophagy induced by the leptin deficiency in ob/ob mice (Fig. 5).

364 The p62 protein interacts with LC3 to remove protein aggregates and is considered a marker of  
365 autophagic flux. The expression of the p62 protein was significantly increased in the ObC group  
366 ( $p<0.05$ ), indicating that autophagic degradation was inefficient. This blockade seems to be resolved in  
367 the ObM group, as p62 expression was reduced to control levels ( $p<0.001$ ). However, the levels of the  
368 p62 protein were significantly increased in the WM group ( $p<0.01$ ), which may be related to antioxidant  
369 defense support [51,52] and were further increased by melatonin (Fig. 5).

370 Thus, leptin deficiency-induced obesity triggers both CMA and macroautophagy as compensatory  
371 cellular mechanisms for maintaining protein homeostasis.

372

### 373 **The leptin deficiency induces aggresome formation**

374 Cytoskeletal alterations are present in numerous diseases. Disruption of the cytoskeleton allows  
375 misfolded proteins to associate with cytoskeletal components and triggers the formation of inclusion  
376 bodies that are generically termed aggresomes [53]. Actin, microtubules, ubiquitinated proteins and  
377 vimentin, the intermediate filament that surrounds these elements, are main elements of these aggregates  
378 [54].

379 Immunoblots for  $\beta$ -actin and vimentin showed similar patterns, but  $\alpha$ -tubulin expression differed from  
380 the levels of these proteins. Brain extracts from leptin-deficient obese mice showed increased expression  
381 of  $\beta$ -actin,  $\alpha$ -tubulin and vimentin compared with wild-type animals ( $p < 0.001$ ). However, the melatonin  
382 treatment increased the  $\beta$ -actin ( $p < 0.001$ ) and vimentin ( $p < 0.05$ ) levels and significantly decreased  $\alpha$ -  
383 tubulin expression in ob/ob mice ( $p < 0.001$ ) (Fig. 6). Disruption of microtubules blocks aggresome  
384 formation [55]; consequently, the significant decrease in the  $\alpha$ -tubulin levels seems to support reduced  
385 aggresome formation in this experimental group.

386 The results observed in the ObC mice indicated effects on neuronal physiology and vesicle trafficking  
387 and could lead to the expression of neurodegenerative markers.

388

### 389 **The leptin deficiency increases the accumulation of neurodegeneration markers**

390 Based on the our results suggesting that some protein quality control mechanisms were impaired and  
391 cytoskeletal rearrangements occurred in ob/ob mice and findings that abnormal aggregates of  
392 cytoskeletal proteins are neuropathological signatures of many neurodegenerative diseases [56], we  
393 studied the expression of the main neurodegeneration markers in our experimental model of morbid  
394 obesity.

395 The  $\beta$ -amyloid and  $\alpha$ -synuclein proteins are markers of Alzheimer's disease (AD) and Parkinson's  
396 disease (PD), respectively, and their deposition is also detected during age-related neurodegeneration.



397 Although ob/ob and wild-type mice presented equal amounts of the  $\beta$ -amyloid protein, with an  
398 unexpected, significant increase in wild-type animals treated with melatonin, ob/ob animals exhibited a  
399 significant increase in  $\alpha$ -synuclein expression ( $p<0.05$ ) (Fig. 7a).

400 Abnormal hyperphosphorylation of the microtubule-associated protein Tau is frequently observed in  
401 neurodegenerative diseases such as AD and even in normal age-related neurodegeneration. We analyzed  
402 four Tau phosphorylation sites: Tau p-S<sup>199</sup>, Tau p-T<sup>205</sup>, Tau p-S<sup>396</sup> and Tau p-S<sup>404</sup>. The levels of  
403 phosphorylation at these sites were similar but were significantly higher in brains from leptin-deficient  
404 ob/ob mice ( $p<0.05$  for Tau p-S<sup>199</sup>,  $p<0.001$  for Tau p-T<sup>205</sup>,  $p<0.01$  for Tau p-S<sup>396</sup> and  $p<0.001$  for Tau  
405 p-S<sup>404</sup>) (Fig. 7b). Although the melatonin treatment did not alter the  $\beta$ -amyloid content in ob/ob mice, it  
406 induced a significant decrease in the  $\alpha$ -synuclein ( $p<0.05$ ) (Fig. 7a) and phosphorylated Tau protein  
407 expression to the levels detected in wild-type mice ( $p<0.001$  for Tau p-S<sup>199</sup>,  $p<0.001$  for Tau p-T<sup>205</sup>,  
408  $p<0.001$  for Tau p-S<sup>396</sup> and  $p<0.001$  for Tau p-S<sup>404</sup>) (Fig. 7b).

409 In summary, based on the results presented in this section, leptin deficiency-induced obesity increases  
410 the accumulation of neurodegeneration markers, mainly markers of tauopathies, and melatonin is able  
411 to restore the normal levels of these markers.

412

### 413 **Leptin-deficient mice exhibit distinct stress-induced behaviors**

414 All previous alterations and failures at the cellular level observed in the brains of ob/ob mice could have  
415 behavioral implications and may be correlated with behavioral changes in response to an acute stressful  
416 and aversive situation. Therefore, we evaluated the possible stress-induced behaviors using the PST.

417 Our results showed significant differences between ob/ob and wild-type mice, as the leptin-deficient  
418 mice exhibited lower immobility latency times ( $p<0.001$ ) (Fig. 8a). This increase in mobility revealed  
419 an escape behavior that suggested a lower state of hopelessness in ob/ob animals than in wild-type mice  
420 (Fig. 8b). The melatonin treatment did not alter the stress-induced behaviors of wild-type animals, but  
421 it reversed this behavior in leptin-deficient mice by reducing mobility and increasing immobility to the  
422 levels observed in wild-type animals ( $p<0.001$ ) (Fig. 8).

423 Thus, the cellular alterations detected in the brains of leptin-deficient mice induce changes in behaviors  
424 by increasing the animals' perception of stress and probably their susceptibility to anxiety.

425

## 426 **Discussion**

427 Obesity, a medical condition that has reached epidemic levels worldwide, is a key factor in several  
428 widely studied diseases, such as bone and muscle diseases, heart diseases and type 2 diabetes [57].

429 Although obesity has been shown to affect the organism from the biochemical level to the tissue level,  
430 its effects on the brain, particularly the impact of obesity-induced damage on the brain, have been poorly  
431 studied. Therefore, we studied the effects of obesity on cellular mechanisms and showed that obesity  
432 induced widespread brain effects that may underlie neurodegenerative disorders ultimately  
433 compromising the behavior. Association between obesity and dementia risk are being studied [4].

434 Morbid obesity, such as is induced in ob/ob mice by leptin absence [58], induced a significant decrease  
435 in brain weight in our animals, even though the net body weight of the ob/ob mice was significantly  
436 increased compared to the wild-type mice. A similar decrease in brain volume is usually observed during  
437 aging and is related to changes in cognition [59]. This concomitant decrease may be the first evidence  
438 of cerebral damage.

439 The decrease in brain volume is not the only similarity between the effects of obesity and aging on the  
440 brain. Oxidative stress occurs in aged brain [60,61], and increased food intake causes the excessive  
441 oxidation of glucose and exacerbates ROS production [62]. In our obese animals, these changes were  
442 manifested as a significant increase in protein damage that was not reduced by GSSG-Px/GR. The  
443 tandem dysregulation of SOD and CAT activities magnifies this damage. As shown in aged brains,  
444 melatonin was able to counteract this damage and significantly reduces brain damage by restoring and  
445 increasing the antioxidant activities of SOD and CAT [63,64].

446 The oxidative stress observed in the brains of our obese animals dysregulates inflammation by inducing  
447 a clear increase in the IL-6 levels and a decrease in the TNF- $\alpha$  levels. IL-6 and leptin are adipokines,  
448 and both proteins, together with their receptors, share structural and functional similarities in regulating  
449 the immune response [65]. Thus, IL-6 expression is increased in response to oxidative stress, generating  
450 a protective anti-inflammatory effect that, in turn, inhibits TNF- $\alpha$  production [66]. The melatonin  
451 treatment enhanced this protective effect of IL-6 on both obese and wild-type animals. Likewise, the

452 slight increase in TNF- $\alpha$  production observed in melatonin-treated obese mice may result from  
453 melatonin-induced improvements in the immune system, consistent with several previous reports [67-  
454 69]. These data agree with the decrease in the levels of this cytokine in obese animals, where the close  
455 relationship between leptin and TNF- $\alpha$  must be assessed [65], since both cytokines exert synergistic  
456 effects and in the absence of one cytokine, the levels of the other may be reduced. Nevertheless, TNF- $\alpha$   
457 reduces food intake and participates in regulating energy homeostasis [70]; in the absence of leptin and  
458 the presence of reduced TNF- $\alpha$  levels, energy homeostasis is expected to be deregulated, suggesting that  
459 the protein synthesis and degradation pathways are impaired.

460 According to previous studies, including studies from our own group, obesity induces ER stress in  
461 different organs [13,66-68]. However, the UPR in the brain has specific and dangerous consequences,  
462 since oxidative stress and protein misfolding play critical roles in the pathogenesis of neurodegenerative  
463 diseases [71-73] and dementia [74]. The ER has an essential role in neurotransmitter synthesis; therefore,  
464 ER stress implies that protein folding efficiency is decreasing, which may contribute to abnormalities in  
465 the neuronal circuitry that may represent a preliminary stage of neurological disorders [75]. Oxidative  
466 stress and ER stress are observed in the brains of obese animals, as shown by the changes in the main  
467 signaling cascades. However, the signals required to trigger these pathways are missing. The primary  
468 target of IRE-1 $\alpha$ /XBP1 activation is the 26S proteasome [73] to reduce the levels of misfolded proteins,  
469 but obese animals showed decreased 20S proteasome activity. Likewise, ATF-6 $\alpha$  is cleaved to yield a  
470 fragment that migrates to the nucleus to activate the transcription of chaperone genes [76], but the levels  
471 of hsc70, one of the most important chaperones that integrates in the hsp70 system and is responsible  
472 for preventing aggregation and remodeling folding pathways [48], are significantly reduced in obese  
473 animals. Although the UPR is correctly triggered by the misfolded proteins, subsequent transcriptional  
474 activation is not produced. These obesity-induced impairments are consistent with data observed in  
475 aging models [77], as the ability to activate the UPR decreases with age. The significant increase in the  
476 levels of ubiquitinated proteins observed in the obese animals indicates that ER stress is not being  
477 resolved. Proteasome dysfunction has been widely documented in obese subjects [78,79]; however, this  
478 study is the first to show the deterioration of the UPR signaling cascade in obese animals.

479 The treatment with melatonin induced a total recovery. Accumulating data support the hypothesis that  
480 protein folding and the generation of free radicals in the ER as byproducts of protein oxidation are  
481 closely associated events [73]. Under these circumstances, the action of potent antioxidants, such as  
482 melatonin, is very beneficial. A minimal UPR was observed in obese animals treated with melatonin  
483 because the production of misfolded proteins was drastically reduced; these data were corroborated by  
484 the substantial reduction in the levels of ubiquitinated proteins in this experimental group.

485 Degradation of misfolded proteins only occurs through the proteasome or autophagy. Both CMA and  
486 macroautophagy were up-regulated in our obese animals. This situation reduced the levels of misfolded  
487 proteins, although misfolded proteins were still present, as shown in the blots of the ubiquitinated  
488 proteins. However, this *status quo* cannot be maintained. Thus, Ignacio-Souza and coworkers [79]  
489 showed that prolonged obesity, but not short-term, trying to maintain rate of protein recycling, induced  
490 eventually ubiquitin/proteasome and autophagy fails. Similar data were observed in our unpublished  
491 data from human muscles obtained from overweight aged people [80]. Thus, sustained autophagy fails  
492 to remove all damaged structures and directs the cell to programmed cell death. The significant increase  
493 in the p62 levels observed in the obese animals showed that autophagy was not as efficient as needed.

494 The melatonin treatment, which reduces ER stress and oxidative stress in the cell, reduces the need for  
495 autophagy, and thus autophagy was significantly reduced in this experimental group. However, the  
496 increased p62 levels observed in control animals treated with melatonin may be noteworthy. P62 is a  
497 multifunctional molecule and the meaning of this result requires additional information. Therefore,  
498 considering the data from the ER stress, oxidative stress, UPR cascade and autophagy experiments, the  
499 most likely role of p62 is to counteract oxidative stress and enhance cell protection by interacting with  
500 nuclear factor-erythroid 2-related factor 2 (Nrf2), as suggested by some authors [52,81]. Thus, our  
501 results about p62 in the treated wild-type animals are probably related with the antioxidant properties of  
502 melatonin.

503 Aggresomes are inclusion bodies composed of misfolded proteins that are aggregated in a single  
504 structure mainly in the central region of the cell [54]. However, several other molecules can be also  
505 incorporated in aggresomes by synergistic actions. Thus, several cytoskeleton components are present  
506 in aggresomes as a result of cytoskeletal disruptions, including intermediate filaments [53], filamentous

507 actin [82] and, mainly in the central nervous system, microtubules, which have dangerous consequences  
508 regarding the transport of neurotransmitters [83]. These aggresomes are also enriched in ubiquitin, a  
509 marker of misfolded proteins, and p62, as this molecule acts a bridge between ubiquitin-protein  
510 aggregates and the autophagosomal system [83]. Inefficient autophagy leads to the accumulation of  
511 autophagosomes enriched in p62 and misfolded/unfolded proteins that assist in the construction of  
512 aggresomes. In obese animals, the levels of p62 and misfolded proteins were increased. Cytoskeletal  
513 rearrangements are also evident, based on the significant increase in the levels of actin, tubulin and  
514 vimentin, supporting the presence of aggresomes. The intermediate filament vimentin is redistributed  
515 during aggresome formation to form a cage surrounding a pericentriolar core composed of ubiquitinated  
516 proteins [55]; therefore, the increase in the vimentin levels should be related to aggresome formation.  
517 Aggresomes gain special importance in obese animals when the brain is the target, since they play a  
518 main role in brain deterioration and directly interact with the hyperphosphorylated Tau protein observed  
519 in these animals, which also forms part of the aggresome [84].

520 Tau is a highly soluble protein with multiple phosphorylation sites [85]. Its microtubule binding activity  
521 is mainly regulated by phosphorylation, and microtubule assembly is promoted by this posttranslational  
522 modification, which stabilizes the microtubule network. However, Tau hyperphosphorylation reduces  
523 its capability to bind microtubules [86] and is present in a large number of neurodegenerative disorders  
524 known as tauopathies [87]. Likewise, filamentous actin interacts with Tau proteins in inclusion bodies  
525 in AD [54,82]. Phosphorylation at four Tau sites was significantly increased in obese animals and are  
526 included in the 30 phosphorylation sites observed in the brain of AD patients [87], indicating that obesity  
527 may be implicated in tauopathies development. Together with these neurodegenerative markers, the  $\alpha$ -  
528 synuclein levels were also increased in ob/ob animals. Its accumulation seems to be induced by the  
529 oxidative environment, misfolded proteins, accelerated aggregation and impairments in degradation  
530 systems, which contribute to the pathogenesis of synucleinopathies [83,88].

531 The melatonin treatment produced a drastic effect on  $\alpha$ -synuclein accumulation, hyperphosphorylation  
532 of Tau and aggresome formation. Melatonin efficiently protects neuronal cells and attenuates  
533 Alzheimer-like Tau hyperphosphorylation via its antioxidant properties [87]. In our study, melatonin  
534 significantly reduced phosphorylation at the four Tau sites studied to the basal level, inhibiting the

535 development of cognitive deficits associated with some tauopathies [89]. Regarding aggresome  
536 formation, the effect of melatonin seems to be mediated by a cascade consisting of reduced oxidative  
537 stress and minimized ER stress to resolve protein misfolding. Thus, autophagy overactivity is not  
538 required to avoid aggresome formation. Moreover, various authors have revealed the importance of  
539 microtubules in the formation and clearance of aggresomes [54,84]; therefore, a significant reduction in  
540  $\alpha$ -tubulin expression in the ObM group is expected to decrease the number of these inclusion bodies.  
541 This effect of melatonin as an inducer of a mechanism preventing aggresome formation was previously  
542 unknown.

543 Tauopathies [90] and synucleinopathies [91] have been described to induce cognitive deficits.  
544 Consequently, all cellular damage observed in the brains of obese animals, together with Tau  
545 hyperphosphorylation and  $\alpha$ -synuclein accumulation, could promote abnormal behaviors. To test this  
546 hypothesis in our experimental model, we used the PST that measure anxiety- and/or depression-related  
547 behaviors since these behaviors are common and prodromal symptoms of neurodegenerative diseases  
548 [92-95]. Although the PST allows us to study depression-related factors, the PST is not a sufficient  
549 screen for depression.

550 Although several studies have correlated low leptin levels in the plasma or cerebrospinal fluid with a  
551 risk of major depression (REFs), leptin deficiency-induced obesity increases mobility latency times,  
552 suggesting an increase in the animals' perception of stress and anxiety [96,97]. On the other hand, the  
553 accumulation of abnormally hyperphosphorylated Tau proteins increases anxiety-related behaviors  
554 [98,99].

555 As discussed above, melatonin significantly reduces the negative effects of obesity on the brain, which  
556 may be sufficient to explain the recovery in stress-induced behaviors until control levels observed in  
557 melatonin-treated obese mice, which presented similar mobility latency times than wild-type animals.  
558 Moreover, anxiolytic and antidepressant-like effects were attributed to melatonin [95,100]. These  
559 multifactorial actions of melatonin are certainly the reason for the evident improvements in the behaviors  
560 of the treated obese animals.

561 In summary, morbid obesity, which was induced by a leptin deficiency in the ob/ob animals, provokes  
562 significant alterations in the brain at cellular level that altered their behaviors. Oxidative stress is

563 accompanied by ER stress in the brains of these animals. Thus, UPR and protein degradation systems  
564 (proteasome, CMA, autophagy, etc.) begin to be overwhelmed, aggresomes are formed, and  
565 neurodegenerative markers are expressed, all of which are also present in non-pathological aging.  
566 Aggresomes always have harmful effects on cell transport, but they are particularly deleterious to  
567 postmitotic neurons, which require neurotransmitter transport and have no capacity to dilute protein  
568 aggregates by cell division, leading to cell death. Finally, these alterations increase the animals'  
569 perception of stress and anxiety.

570 Melatonin improves the antioxidant defense system by reducing the levels of damaged and  
571 unfolded/misfolded proteins, thus attenuating the failure of the protein repair and degradation systems  
572 and decreasing the levels of protein aggregates and brain damage caused by obesity. Additionally, the  
573 melatonin treatment decreases the stress-induced behaviors and anxiety. Therefore, our results suggest  
574 that melatonin is a potential therapeutic agent that protects against brain damage in obesity specifically  
575 tested.

576

## 577 **Acknowledgments**

578 We are members of the cROS group and the INPROTEOLYS and INEUROPA networks. This work  
579 was supported by FISS-13-RD12/0043/0030, FISS-13-RD12/0043/0017 and FISS-14-PI13/02741  
580 (Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness), FC-15-GRUPIN14-  
581 071 (FICYT, PCTI, Principado de Asturias) and FEDER funds. A. Rubio-González and Z. Pérez-  
582 Martínez are pre-doctoral hires (FC-15-GRUPIN14-071) from FICYT, PCTI (Principado de Asturias).  
583 Y. Potes is a FISS pre-doctoral fellow (FI14/00405) from the Instituto de Salud Carlos III (Spanish  
584 Ministry of Economy and Competitiveness).

585

## 586 **Conflict of interest**

587 The authors declare that they have no conflict of interest.

588

## 589 **References**

- 590 1. WHO (2015) Obesity and Overweight. World Health Organization (WHO).  
591 <http://www.who.int/mediacentre/factsheets/fs311/es/>. Accessed 6 March 2017
- 592 2. Haslam DW, James WP (2005) Obesity. *Lancet* 366:1197-1209. doi:10.1016/S0140-6736(05)67483-  
593 1
- 594 3. Beydoun MA, Beydoun HA, Wang Y (2008) Obesity and central obesity as risk factors for incident  
595 dementia and its subtypes: a systematic review and meta-analysis. *Obesity reviews : an official journal*  
596 *of the International Association for the Study of Obesity* 9:204-218. doi:10.1111/j.1467-  
597 789X.2008.00473.x
- 598 4. Lee EB, Mattson MP (2014) The neuropathology of obesity: insights from human disease. *Acta*  
599 *neuropathologica* 127:3-28. doi:10.1007/s00401-013-1190-x
- 600 5. Marwarha G, Dasari B, Prasanthi JR, Schommer J, Ghribi O (2010) Leptin reduces the accumulation  
601 of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. *Journal*  
602 *of Alzheimer's disease : JAD* 19:1007-1019. doi:10.3233/JAD-2010-1298
- 603 6. Raichle ME, Gusnard DA (2002) Appraising the brain's energy budget. *Proceedings of the National*  
604 *Academy of Sciences of the United States of America* 99:10237-10239. doi:10.1073/pnas.172399499
- 605 7. Reiter RJ (1995) Oxidative processes and antioxidative defense mechanisms in the aging brain.  
606 *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*  
607 9:526-533
- 608 8. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA (2008) Autophagy induction and  
609 autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *The*  
610 *Journal of neuroscience : the official journal of the Society for Neuroscience* 28:6926-6937.  
611 doi:10.1523/JNEUROSCI.0800-08.2008
- 612 9. Hoyer-Hansen M, Jaattela M (2007) Connecting endoplasmic reticulum stress to autophagy by  
613 unfolded protein response and calcium. *Cell death and differentiation* 14:1576-1582.  
614 doi:10.1038/sj.cdd.4402200
- 615 10. Zhang N, Cao MM, Liu H, Xie GY, Li YB (2015) Autophagy regulates insulin resistance following  
616 endoplasmic reticulum stress in diabetes. *Journal of physiology and biochemistry* 71:319-327.  
617 doi:10.1007/s13105-015-0384-1



- 618 11. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by  
619 protein aggregation. *Science* 292:1552-1555. doi:10.1126/science.292.5521.1552
- 620 12. Coto-Montes A, Boga JA, Rosales-Corral S, Fuentes-Broto L, Tan DX, Reiter RJ (2012) Role of  
621 melatonin in the regulation of autophagy and mitophagy: a review. *Molecular and cellular*  
622 *endocrinology* 361:12-23. doi:10.1016/j.mce.2012.04.009
- 623 13. de Luxan-Delgado B, Potes Y, Rubio-Gonzalez A, Caballero B, Solano JJ, Fernandez-Fernandez M,  
624 Bermudez M, Rodrigues Moreira Guimaraes M, Vega-Naredo I, Boga JA, Coto-Montes A (2016)  
625 Melatonin reduces endoplasmic reticulum stress and autophagy in liver of leptin-deficient mice. *Journal*  
626 *of pineal research* 61:108-123. doi:10.1111/jpi.12333
- 627 14. Bonda DJ, Stone JG, Torres SL, Siedlak SL, Perry G, Kryscio R, Jicha G, Casadesus G, Smith MA,  
628 Zhu X, Lee HG (2014) Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal  
629 leptin resistance. *Journal of neurochemistry* 128:162-172. doi:10.1111/jnc.12380
- 630 15. Turner RT, Philbrick KA, Wong CP, Olson DA, Branscum AJ, Iwaniec UT (2014) Morbid obesity  
631 attenuates the skeletal abnormalities associated with leptin deficiency in mice. *The Journal of*  
632 *endocrinology* 223:M1-15. doi:10.1530/JOE-14-0224
- 633 16. Reiter RJ, Tan DX, Korkmaz A, Ma S (2012) Obesity and metabolic syndrome: association with  
634 chronodisruption, sleep deprivation, and melatonin suppression. *Annals of medicine* 44:564-577.  
635 doi:10.3109/07853890.2011.586365
- 636 17. Vega-Naredo I, Caballero B, Sierra V, Garcia-Macia M, de Gonzalo-Calvo D, Oliveira PJ,  
637 Rodriguez-Colunga MJ, Coto-Montes A (2012) Melatonin modulates autophagy through a redox-  
638 mediated action in female Syrian hamster Harderian gland controlling cell types and gland activity.  
639 *Journal of pineal research* 52 (1):80-92. doi:10.1111/j.1600-079X.2011.00922.x
- 640 18. Mastronardi CA, Walczewska A, Yu WH, Karanth S, Parlow AF, McCann SM (2000) The possible  
641 role of prolactin in the circadian rhythm of leptin secretion in male rats. *Proc Soc Exp Biol Med* 224:152-  
642 158
- 643 19. Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernandez-Vazquez G (2012) Melatonin improves  
644 glucose homeostasis in young Zucker diabetic fatty rats. *Journal of pineal research* 52:203-210.  
645 doi:10.1111/j.1600-079X.2011.00928.x

- 646 20. Canpolat S, Sandal S, Yilmaz B, Yasar A, Kutlu S, Baydas G, Kelestimur H (2001) Effects of  
647 pinealectomy and exogenous melatonin on serum leptin levels in male rat. *European journal of*  
648 *pharmacology* 428:145-148
- 649 21. Baydas G, Gursu F, Canpolat S, Konar V, Yasar A, Canatan H, Kelestimur H (2001) Effects of  
650 pinealectomy on the circadian release pattern of leptin in male rat. *Neuro endocrinology letters* 22:449-  
651 452
- 652 22. Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, Vriend J, Tan DX,  
653 Reiter RJ (2015) Melatonin: an ancient molecule that makes oxygen metabolically tolerable. *Journal of*  
654 *pineal research* 59:403-419. doi:10.1111/jpi.12267
- 655 23. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L (2016) Melatonin as an  
656 antioxidant: under promises but over delivers. *Journal of pineal research* 61:253-278.  
657 doi:10.1111/jpi.12360
- 658 24. Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ (2011) Significance and  
659 application of melatonin in the regulation of brown adipose tissue metabolism: relation to human  
660 obesity. *Obesity reviews : an official journal of the International Association for the Study of Obesity*  
661 12:167-188. doi:10.1111/j.1467-789X.2010.00756.x
- 662 25. Jimenez-Aranda A, Fernandez-Vazquez G, Campos D, Tassi M, Velasco-Perez L, Tan DX, Reiter  
663 RJ, Agil A (2013) Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty  
664 rats. *Journal of pineal research* 55:416-423. doi:10.1111/jpi.12089
- 665 26. Lima FB, Machado UF, Bartol I, Seraphim PM, Sumida DH, Moraes SM, Hell NS, Okamoto MM,  
666 Saad MJ, Carvalho CR, Cipolla-Neto J (1998) Pinealectomy causes glucose intolerance and decreases  
667 adipose cell responsiveness to insulin in rats. *The American journal of physiology* 275:E934-941
- 668 27. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M (2011)  
669 Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients  
670 with metabolic syndrome. *Journal of pineal research* 50:261-266. doi:10.1111/j.1600-  
671 079X.2010.00835.x
- 672 28. Wu H, Shao A, Zhao M, Chen S, Yu J, Zhou J, Liang F, Shi L, Dixon BJ, Wang Z, Ling C, Hong  
673 Y, Zhang J (2016) Melatonin attenuates neuronal apoptosis through up-regulation of K(+) -Cl(-)

674 cotransporter KCC2 expression following traumatic brain injury in rats. *Journal of pineal research*  
675 61:241-250. doi:10.1111/jpi.12344

676 29. Castracane VD, Henson MC (2007) The obese (ob/ob) mouse and the discovery of leptin. In:  
677 Castracane VD, Henson MC (eds) *Leptin. Endocrine Updates*, vol 25. Springer US, New York City,  
678 NY, USA, pp 1-9. doi:10.1007/978-0-387-31416-7\_1

679 30. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of  
680 protein utilizing the principle of protein-dye binding. *Analytical biochemistry* 72:248-254

681 31. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman  
682 ER (1990) Determination of carbonyl content in oxidatively modified proteins. *Methods in enzymology*  
683 186:464-478

684 32. Coto-Montes A, Hardeland R (1999) Antioxidative effects of melatonin in *Drosophila melanogaster*:  
685 antagonization of damage induced by the inhibition of catalase. *Journal of pineal research* 27:154-158

686 33. Arnao MB, Cano A, Acosta M (2001) The hydrophilic and lipophilic contribution to total antioxidant  
687 activity. *Food Chemistry* 73:239-244

688 34. de Gonzalo-Calvo D, Neitzert K, Fernandez M, Vega-Naredo I, Caballero B, Garcia-Macia M,  
689 Suarez FM, Rodriguez-Colunga MJ, Solano JJ, Coto-Montes A (2010) Differential inflammatory  
690 responses in aging and disease: TNF-alpha and IL-6 as possible biomarkers. *Free radical biology &*  
691 *medicine* 49:733-737. doi:10.1016/j.freeradbiomed.2010.05.019

692 35. Martin JP, Jr., Dailey M, Sugarman E (1987) Negative and positive assays of superoxide dismutase  
693 based on hematoxylin autoxidation. *Archives of biochemistry and biophysics* 255:329-336

694 36. Lubinsky S, Bewley GC (1979) Genetics of Catalase in *DROSOPHILA MELANOGASTER*: Rates  
695 of Synthesis and Degradation of the Enzyme in Flies Aneuploid and Euploid for the Structural Gene.  
696 *Genetics* 91:723-742

697 37. Kum-Tatt L, Tan IK, Seet AM (1975) A new colorimetric method for the determination of  
698 NADH/NADPH dependent glutathione reductase in erythrocytes and in plasma. *Clinica chimica acta;*  
699 *international journal of clinical chemistry* 58:101-108

700 38. Goldberg DM, Spooner RJ (1983) Glutathione reductase. In: Bergmeyer HU (ed) *Methods of*  
701 *enzymatic analysis*. 3rd ed. edn. Verlag Chemie, Deerfield Beach, FL, pp 258-265

- 702 39. Nugent BM, Wright CL, Shetty AC, Hodes GE, Lenz KM, Mahurkar A, Russo SJ, Devine SE,  
703 McCarthy MM (2015) Brain feminization requires active repression of masculinization via DNA  
704 methylation. *Nature neuroscience* 18 (5):690-697. doi:10.1038/nn.3988
- 705 40. Oliván M, Fernández-Suárez V, Díaz-Martínez F, Sierra V, Coto-Montes A, de Luxán-Delgado B,  
706 Peña R, Bassols A, Fàbrega E, Dalmau A, Velarde A (2016) Identification of biomarkers of stress in  
707 meat of pigs managed under different mixing treatments. *British Biotechnology Journal* 11:1-13.  
708 doi:10.9734/BBJ/2016/22402
- 709 41. Havlis J, Thomas H, Sebela M, Shevchenko A (2003) Fast-response proteomics by accelerated in-  
710 gel digestion of proteins. *Analytical chemistry* 75:1300-1306
- 711 42. Jami MS, Barreiro C, Garcia-Estrada C, Martín JF (2010) Proteome analysis of the penicillin  
712 producer *Penicillium chrysogenum*: characterization of protein changes during the industrial strain  
713 improvement. *Molecular & cellular proteomics : MCP* 9:1182-1198. doi:10.1074/mcp.M900327-  
714 MCP200
- 715 43. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for  
716 antidepressants. *Archives internationales de pharmacodynamie et de therapie* 229:327-336
- 717 44. Gersner R, Dar DE, Shabat-Simon M, Zangen A (2005) Behavioral analysis during the forced  
718 swimming test using a joystick device. *Journal of neuroscience methods* 143:117-121.  
719 doi:10.1016/j.jneumeth.2004.09.017
- 720 45. Dandekar A, Mendez R, Zhang K (2015) Cross talk between ER stress, oxidative stress, and  
721 inflammation in health and disease. *Methods in molecular biology* 1292:205-214. doi:10.1007/978-1-  
722 4939-2522-3\_15
- 723 46. Yoo YM (2013) Melatonin-mediated insulin synthesis during endoplasmic reticulum stress involves  
724 HuD expression in rat insulinoma INS-1E cells. *Journal of pineal research* 55:207-220.  
725 doi:10.1111/jpi.12064
- 726 47. Yoshida H, Matsui T, Hosokawa N, Kaufman RJ, Nagata K, Mori K (2003) A time-dependent phase  
727 shift in the mammalian unfolded protein response. *Developmental cell* 4:265-271

728 48. Mashaghi A, Bezrukavnikov S, Minde DP, Wentink AS, Kityk R, Zachmann-Brand B, Mayer MP,  
729 Kramer G, Bukau B, Tans SJ (2016) Alternative modes of client binding enable functional plasticity of  
730 Hsp70. *Nature* 539:448-451. doi:10.1038/nature20137

731 49. Wu J, Rutkowski DT, Dubois M, Swathirajan J, Saunders T, Wang J, Song B, Yau GD, Kaufman  
732 RJ (2007) ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic  
733 stress. *Developmental cell* 13:351-364. doi:10.1016/j.devcel.2007.07.005

734 50. Vega-Naredo I, Caballero B, Sierra V, Huidobro-Fernandez C, de Gonzalo-Calvo D, Garcia-Macia  
735 M, Tolivia D, Rodriguez-Colunga MJ, Coto-Montes A (2009) Sexual dimorphism of autophagy in  
736 Syrian hamster Harderian gland culminates in a holocrine secretion in female glands. *Autophagy*  
737 5:1004-1017

738 51. Reinisalo M, Karlund A, Koskela A, Kaarniranta K, Karjalainen RO (2015) Polyphenol Stilbenes:  
739 Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related Diseases. *Oxidative*  
740 *medicine and cellular longevity* 2015:340520. doi:10.1155/2015/340520

741 52. Rusten TE, Stenmark H (2010) p62, an autophagy hero or culprit? *Nature cell biology* 12:207-209.  
742 doi:10.1038/ncb0310-207

743 53. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. *Trends in cell biology*  
744 10:524-530

745 54. Lazaro-Dieguez F, Aguado C, Mato E, Sanchez-Ruiz Y, Esteban I, Alberch J, Knecht E, Egea G  
746 (2008) Dynamics of an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide.  
747 *Journal of cell science* 121:1415-1425. doi:10.1242/jcs.017665

748 55. Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins.  
749 *The Journal of cell biology* 143:1883-1898

750 56. Cairns NJ, Lee VM, Trojanowski JQ (2004) The cytoskeleton in neurodegenerative diseases. *The*  
751 *Journal of pathology* 204:438-449. doi:10.1002/path.1650

752 57. Cao JJ (2011) Effects of obesity on bone metabolism. *Journal of orthopaedic surgery and research*  
753 6:30. doi:10.1186/1749-799X-6-30

754 58. Dubern B, Clement K (2012) Leptin and leptin receptor-related monogenic obesity. *Biochimie*  
755 94:2111-2115. doi:10.1016/j.biochi.2012.05.010

756 59. Hedman AM, van Haren NE, Schnack HG, Kahn RS, Hulshoff Pol HE (2012) Human brain changes  
757 across the life span: a review of 56 longitudinal magnetic resonance imaging studies. *Human brain*  
758 *mapping* 33:1987-2002. doi:10.1002/hbm.21334

759 60. Caballero B, Coto-Montes A (2012) An insight into the role of autophagy in cell responses in the  
760 aging and neurodegenerative brain. *Histology and histopathology* 27:263-275. doi:10.14670/HH-27.263

761 61. Alvarez-Garcia O, Vega-Naredo I, Sierra V, Caballero B, Tomas-Zapico C, Camins A, Garcia JJ,  
762 Pallas M, Coto-Montes A (2006) Elevated oxidative stress in the brain of senescence-accelerated mice  
763 at 5 months of age. *Biogerontology* 7:43-52. doi:10.1007/s10522-005-6041-2

764 62. Manna P, Jain SK (2015) Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated  
765 Health Risks: Causes and Therapeutic Strategies. *Metabolic syndrome and related disorders* 13:423-  
766 444. doi:10.1089/met.2015.0095

767 63. Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernandez C, Soria-Valles C, De Gonzalo-Calvo  
768 D, Tolivia D, Gutierrez-Cuesta J, Pallas M, Camins A, Rodriguez-Colunga MJ, Coto-Montes A (2008)  
769 Favorable effects of a prolonged treatment with melatonin on the level of oxidative damage and  
770 neurodegeneration in senescence-accelerated mice. *Journal of pineal research* 45:302-311.  
771 doi:10.1111/j.1600-079X.2008.00591.x

772 64. Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernandez C, Soria-Valles C, De Gonzalo-Calvo  
773 D, Tolivia D, Pallas M, Camins A, Rodriguez-Colunga MJ, Coto-Montes A (2009) Melatonin alters cell  
774 death processes in response to age-related oxidative stress in the brain of senescence-accelerated mice.  
775 *Journal of pineal research* 46:106-114. doi:10.1111/j.1600-079X.2008.00637.x

776 65. Fantuzzi G, Faggioni R (2000) Leptin in the regulation of immunity, inflammation, and  
777 hematopoiesis. *Journal of leukocyte biology* 68:437-446

778 66. Erta M, Quintana A, Hidalgo J (2012) Interleukin-6, a major cytokine in the central nervous system.  
779 *International journal of biological sciences* 8:1254-1266. doi:10.7150/ijbs.4679

780 67. Pierpaoli W (1998) Neuroimmunomodulation of aging. A program in the pineal gland. *Annals of*  
781 *the New York Academy of Sciences* 840:491-497

782 68. Szczepanik M (2007) Melatonin and its influence on immune system. *Journal of physiology and*  
783 *pharmacology : an official journal of the Polish Physiological Society* 58 Suppl 6:115-124

784 69. Carrillo-Vico A, Lardone PJ, Alvarez-Sanchez N, Rodriguez-Rodriguez A, Guerrero JM (2013)  
785 Melatonin: buffering the immune system. *International journal of molecular sciences* 14:8638-8683.  
786 doi:10.3390/ijms14048638

787 70. Rizk NM, Stammsen D, Preibisch G, Eckel JR (2001) Leptin and Tumor Necrosis Factor-alpha  
788 Induce the Tyrosine Phosphorylation of Signal Transducer and Activator of Transcription Proteins in  
789 the Hypothalamus of Normal Rats In Vivo. *Endocrinology* 142:3027-3032.  
790 doi:10.1210/endo.142.7.8225

791 71. Lee H, Noh JY, Oh Y, Kim Y, Chang JW, Chung CW, Lee ST, Kim M, Ryu H, Jung YK (2012)  
792 IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition  
793 of autophagy flux. *Human molecular genetics* 21:101-114. doi:10.1093/hmg/ddr445

794 72. Torres M, Matamala JM, Duran-Aniotz C, Cornejo VH, Foley A, Hetz C (2015) ER stress signaling  
795 and neurodegeneration: At the intersection between Alzheimer's disease and Prion-related disorders.  
796 *Virus research* 207:69-75. doi:10.1016/j.virusres.2014.12.018

797 73. Malhotra JD, Kaufman RJ (2007) Endoplasmic reticulum stress and oxidative stress: a vicious cycle  
798 or a double-edged sword? *Antioxidants & redox signaling* 9:2277-2293. doi:10.1089/ars.2007.1782

799 74. Mizuno D, Kawahara M (2013) The molecular mechanisms of zinc neurotoxicity and the  
800 pathogenesis of vascular type senile dementia. *International journal of molecular sciences* 14:22067-  
801 22081. doi:10.3390/ijms141122067

802 75. Nosyreva E, Kavalali ET (2010) Activity-dependent augmentation of spontaneous  
803 neurotransmission during endoplasmic reticulum stress. *The Journal of neuroscience : the official*  
804 *journal of the Society for Neuroscience* 30:7358-7368. doi:10.1523/JNEUROSCI.5358-09.2010

805 76. Volmer R, Ron D (2015) Lipid-dependent regulation of the unfolded protein response. *Current*  
806 *opinion in cell biology* 33:67-73. doi:10.1016/j.ceb.2014.12.002

807 77. Taylor RC (2016) Aging and the UPR(ER). *Brain research* 1648:588-593.  
808 doi:10.1016/j.brainres.2016.04.017

809 78. Bollinger LM, Powell JJ, Houmard JA, Witczak CA, Brault JJ (2015) Skeletal muscle myotubes in  
810 severe obesity exhibit altered ubiquitin-proteasome and autophagic/lysosomal proteolytic flux. *Obesity*  
811 23:1185-1193. doi:10.1002/oby.21081

812 79. Ignacio-Souza LM, Bombassaro B, Pascoal LB, Portovedo MA, Razolli DS, Coope A, Victorio SC,  
813 de Moura RF, Nascimento LF, Arruda AP, Anhe GF, Milanski M, Velloso LA (2014) Defective  
814 regulation of the ubiquitin/proteasome system in the hypothalamus of obese male mice. *Endocrinology*  
815 155:2831-2844. doi:10.1210/en.2014-1090

816 80. Potes Y, de Luxan-Delgado B, Rodriguez-Gonzalez S, Guimaraes MRM, Solano JJ, Fernandez-  
817 Fernandez M, Bermudez M, Boga JA, Vega-Naredo I, Coto-Montes A (2017) Overweight in elderly  
818 people induces impaired autophagy in skeletal muscle. *Free radical biology & medicine* 110:31-41.  
819 doi:10.1016/j.freeradbiomed.2017.05.018

820 81. Wang L, Cano M, Handa JT (2014) p62 provides dual cytoprotection against oxidative stress in the  
821 retinal pigment epithelium. *Biochimica et biophysica acta* 1843:1248-1258.  
822 doi:10.1016/j.bbamcr.2014.03.016

823 82. Santa-Maria I, Hernandez F, Moreno FJ, Avila J (2007) Taurine, an inducer for tau polymerization  
824 and a weak inhibitor for amyloid-beta-peptide aggregation. *Neuroscience letters* 429:91-94.  
825 doi:10.1016/j.neulet.2007.09.068

826 83. Richter-Landsberg C, Leyk J (2013) Inclusion body formation, macroautophagy, and the role of  
827 HDAC6 in neurodegeneration. *Acta neuropathologica* 126:793-807. doi:10.1007/s00401-013-1158-x

828 84. Bauer NG, Richter-Landsberg C (2006) The dynamic instability of microtubules is required for  
829 aggresome formation in oligodendroglial cells after proteolytic stress. *Journal of molecular neuroscience*  
830 : MN 29:153-168. doi:10.1385/JMN:29:2:153

831 85. Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. *Molecular neurodegeneration*  
832 4:13. doi:10.1186/1750-1326-4-13

833 86. Schneider A, Mandelkow E (2008) Tau-based treatment strategies in neurodegenerative diseases.  
834 *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 5:443-  
835 457. doi:10.1016/j.nurt.2008.05.006

836 87. Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q (2013) Melatonin in Alzheimer's disease.  
837 *International journal of molecular sciences* 14:14575-14593. doi:10.3390/ijms140714575



838 88. Fellner L, Jellinger KA, Wenning GK, Stefanova N (2011) Glial dysfunction in the pathogenesis of  
839 alpha-synucleinopathies: emerging concepts. *Acta neuropathologica* 121:675-693. doi:10.1007/s00401-  
840 011-0833-z

841 89. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies  
842 P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo  
843 T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM,  
844 Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ,  
845 Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease  
846 neuropathologic changes with cognitive status: a review of the literature. *Journal of neuropathology and*  
847 *experimental neurology* 71:362-381. doi:10.1097/NEN.0b013e31825018f7

848 90. Xiao H, Run X, Cao X, Su Y, Sun Z, Tian C, Sun S, Liang Z (2013) Temperature control can abolish  
849 anesthesia-induced tau hyperphosphorylation and partly reverse anesthesia-induced cognitive  
850 impairment in old mice. *Psychiatry and clinical neurosciences* 67:493-500. doi:10.1111/pcn.12091

851 91. Zhao X, Sun X, Cai S, Ran D, Yan Y, Pei Z (2015) Role of alpha-synuclein in cognitive dysfunction:  
852 Studies in *Drosophila melanogaster*. *Molecular medicine reports* 12:2683-2688.  
853 doi:10.3892/mmr.2015.3763

854 92. Porter VR, Buxton WG, Fairbanks LA, Strickland T, O'Connor SM, Rosenberg-Thompson S,  
855 Cummings JL (2003) Frequency and characteristics of anxiety among patients with Alzheimer's disease  
856 and related dementias. *The Journal of neuropsychiatry and clinical neurosciences* 15:180-186.  
857 doi:10.1176/jnp.15.2.180

858 93. Santos LE, Beckman D, Ferreira ST (2016) Microglial dysfunction connects depression and  
859 Alzheimer's disease. *Brain, behavior, and immunity* 55:151-165. doi:10.1016/j.bbi.2015.11.011

860 94. Teri L, Ferretti LE, Gibbons LE, Logsdon RG, McCurry SM, Kukull WA, McCormick WC, Bowen  
861 JD, Larson EB (1999) Anxiety of Alzheimer's disease: prevalence, and comorbidity. *The journals of*  
862 *gerontology Series A, Biological sciences and medical sciences* 54:M348-352

863 95. Mack JM, Schamne MG, Sampaio TB, Pertile RA, Fernandes PA, Markus RP, Prediger RD (2016)  
864 Melatonergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and

865 Nonmotor Symptoms. *Oxidative medicine and cellular longevity* 2016:3472032.  
866 doi:10.1155/2016/3472032

867 96. Westling S, Ahren B, Traskman-Bendz L, Westrin A (2004) Low CSF leptin in female suicide  
868 attempters with major depression. *Journal of affective disorders* 81:41-48.  
869 doi:10.1016/j.jad.2003.07.002

870 97. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T (2002) Body weight, the  
871 tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine.  
872 *Pharmacopsychiatry* 35:220-225. doi:10.1055/s-2002-36390

873 98. Ng RC, Cheng OY, Jian M, Kwan JS, Ho PW, Cheng KK, Yeung PK, Zhou LL, Hoo RL, Chung  
874 SK, Xu A, Lam KS, Chan KH (2016) Chronic adiponectin deficiency leads to Alzheimer's disease-like  
875 cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in  
876 aged mice. *Molecular neurodegeneration* 11:71. doi:10.1186/s13024-016-0136-x

877 99. Wu B, Wei Y, Wang Y, Su T, Zhou L, Liu Y, He R (2015) Gavage of D-Ribose induces Abeta-like  
878 deposits, Tau hyperphosphorylation as well as memory loss and anxiety-like behavior in mice.  
879 *Oncotarget* 6:34128-34142. doi:10.18632/oncotarget.6021

880 100. Guardiola-Lemaitre B, Lenegre A, Porsolt RD (1992) Combined effects of diazepam and melatonin  
881 in two tests for anxiolytic activity in the mouse. *Pharmacology, biochemistry, and behavior* 41:405-408  
882  
883

884 **Table footnotes**

885 **Table 1** The data are shown as the mean  $\pm$  SD, and were calculated from at least three separate  
886 experiments performed in triplicate. WC, wild-type; WM, wild-type plus melatonin; ObC, ob/ob; ObM,  
887 ob/ob plus melatonin. # wild-type vs. ob/ob and \* melatonin-treated animals vs. melatonin-untreated  
888 animals. # $p < 0.05$ , \* $p < 0.05$ , ## $p < 0.01$ , \*\* $p < 0.01$ , ### $p < 0.001$ , \*\*\* $p < 0.001$ .

889

890 **Figure captions**

891 **Fig. 1** Oxidative damage and antioxidant defense in the brain of wild-type and ob/ob mice. (a) Protein  
892 damage was expressed as nmol carbonylated protein/mg protein. (b) Total antioxidant activity (TAA)  
893 was expressed as equivalents of mg equivalents Trolox/mg protein. (c) Superoxide dismutase (SOD)  
894 activity was expressed as SOD units/mg protein. (d) Catalase (CAT) activity was expressed as  $\mu\text{mol}$   
895  $\text{H}_2\text{O}_2/\text{mg protein} \cdot \text{min}$ . (e) Glutathione peroxidase (GPx) activity was expressed as  $\mu\text{mol NADPH}/\text{mg}$   
896  $\text{protein} \cdot \text{min}$ . (f) Glutathione reductase (GR) activity was expressed as  $\mu\text{mol NADPH}/\text{mg protein} \cdot \text{min}$ .  
897 The data are presented as the mean values  $\pm$  standard deviations (SD) of the means. All data presented  
898 representative data obtained from at least three separate experiments. WC, wild-type; WM, wild-type  
899 plus melatonin; ObC, ob/ob; ObM, ob/ob plus melatonin. # wild-type vs. ob/ob and \* melatonin-treated  
900 animals vs. untreated animals. # $p < 0.05$ , \* $p < 0.05$ , ## $p < 0.01$ , \*\* $p < 0.01$ , ### $p < 0.001$ , \*\*\* $p < 0.001$ .

901

902 **Fig. 2** Inflammatory markers from the brain of wild-type and ob/ob mice. Tumour necrosis factor  $\alpha$   
903 (TNF- $\alpha$ ) and interleukin 6 (IL-6) levels were expressed as pg/mg protein. The data are presented as the  
904 mean values  $\pm$  standard deviations (SD) of the means. All data presented representative data obtained  
905 from at least three separate experiments. WC, wild-type; WM, wild-type plus melatonin; ObC, ob/ob;  
906 ObM, ob/ob plus melatonin. # wild-type vs. ob/ob and \* melatonin-treated animals vs. untreated  
907 animals. # $p < 0.05$ , \* $p < 0.05$ , ## $p < 0.01$ , \*\* $p < 0.01$ , ### $p < 0.001$ , \*\*\* $p < 0.001$ .

908

909 **Fig. 3** Endoplasmic reticulum (ER) stress markers in the brain of wild-type and ob/ob mice. (a) Bar  
910 chart showing the semiquantitative optical density (arbitrary units of blots bands) of inositol-requiring

911 enzyme 1 $\alpha$  (IRE1 $\alpha$ ), phosphorylated-eukaryotic initiation factor 2 $\alpha$  (p-eIF2 $\alpha$ ) and activating  
912 transcription factor-6 $\alpha$  (ATF-6 $\alpha$ ) from western blot normalized to ponceau and expressed as percent  
913 change from the WC sample. (b) Bar chart showing the semiquantitative optical density (arbitrary units  
914 of blots bands) of heat shock cognate 71 kDa (hsc70) protein from sodium dodecyl sulfate-  
915 polyacrylamide gel image of protein extracts of the brain obtained from analysis by matrix-assisted laser  
916 desorption/ionization-time of flight (MALDI-TOF/TOF) mass spectrometry. The results were expressed  
917 as percent change from the WC sample. The data are presented as the mean values  $\pm$  standard deviations  
918 (SD) of the means. All data presented representative data obtained from at least three separate  
919 experiments. WC, wild-type; WM, wild-type plus melatonin; ObC, ob/ob; ObM, ob/ob plus melatonin.  
920 # wild-type vs. ob/ob and \* melatonin-treated animals vs. untreated animals. # $p$ <0.05, \* $p$ <0.05,  
921 ## $p$ <0.01, \*\* $p$ <0.01, ### $p$ <0.001, \*\*\* $p$ <0.001.

922

923 **Fig. 4** Ubiquitin-Proteasome system in the brain of wild-type and ob/ob mice. (a) 20S proteasome  
924 activity is expressed as arbitrary fluorescence  $\mu$ M AMC/mg protein. (b) Bar chart showing the  
925 semiquantitative optical density (arbitrary units of blots bands) of ubiquitin from western blot  
926 normalized to ponceau and expressed as percent change from the WC sample. The data are presented as  
927 the mean values  $\pm$  standard deviations (SD) of the means. All data presented representative data obtained  
928 from at least three separate experiments. WC, wild-type; WM, wild-type plus melatonin; ObC, ob/ob;  
929 ObM, ob/ob plus melatonin. # wild-type vs. ob/ob and \* melatonin-treated animals vs. untreated  
930 animals. # $p$ <0.05, \* $p$ <0.05, ## $p$ <0.01, \*\* $p$ <0.01, ### $p$ <0.001, \*\*\* $p$ <0.001.

931

932 **Fig. 5** Autophagy markers in the brain of wild-type and ob/ob mice. Bar chart showing the  
933 semiquantitative optical density (arbitrary units of blots bands) of lysosome associated membrane  
934 protein type 2A (LAMP2A), Beclin-1, microtubule-associated protein 1 light chain 3 I (LC3-I),  
935 microtubule-associated protein 1 light chain 3 II (LC3-II) and p62 from western blot normalized to  
936 ponceau and expressed as percent change from the WC sample. The data are presented as the mean  
937 values  $\pm$  standard deviations (SD) of the means. All data presented representative data obtained from at  
938 least three separate experiments. WC, wild-type; WM, wild-type plus melatonin; ObC, ob/ob; ObM,

939 ob/ob plus melatonin. # wild-type vs. ob/ob and \* melatonin-treated animals vs. untreated animals.  
940 # $p < 0.05$ , \* $p < 0.05$ , ## $p < 0.01$ , \*\* $p < 0.01$ , ### $p < 0.001$ , \*\*\* $p < 0.001$ .

941

942 **Fig. 6** Cytoskeleton markers in the brain of wild-type and ob/ob mice. Bar chart showing the  
943 semiquantitative optical density (arbitrary units of blots bands) of  $\beta$ -actin,  $\alpha$ -tubulin and vimentin from  
944 western blot normalized to ponceau and expressed as percent change from the WC sample. The data  
945 are presented as the mean values  $\pm$  standard deviations (SD) of the means. All data presented  
946 representative data obtained from at least three separate experiments. WC, wild-type; WM, wild-type  
947 plus melatonin; ObC, ob/ob; ObM, ob/ob plus melatonin. # wild-type vs. ob/ob and \* melatonin-treated  
948 animals vs. untreated animals. # $p < 0.05$ , \* $p < 0.05$ , ## $p < 0.01$ , \*\* $p < 0.01$ , ### $p < 0.001$ , \*\*\* $p < 0.001$ .

949

950 **Fig. 7** Neurodegeneration markers in the brain of wild-type and ob/ob mice. (a) Bar chart showing the  
951 semiquantitative optical density (arbitrary units of blots bands) of  $\beta$ -amyloid and  $\alpha$ -synuclein from  
952 western blot normalized to ponceau and expressed as percent change from the WC sample. (b) Bar chart  
953 showing the semiquantitative optical density (arbitrary units of blots bands) of Tau pS<sup>199</sup>, Tau pT<sup>205</sup>, Tau  
954 pS<sup>396</sup> and Tau pS<sup>404</sup> from western blot normalized to ponceau and expressed as percent change from the  
955 WC sample. The data are presented as the mean values  $\pm$  standard deviations (SD) of the means. All  
956 data presented representative data obtained from at least three separate experiments. WC, wild-type;  
957 WM, wild-type plus melatonin; ObC, ob/ob; ObM, ob/ob plus melatonin. # wild-type vs. ob/ob and \*  
958 melatonin-treated animals vs. untreated animals. # $p < 0.05$ , \* $p < 0.05$ , ## $p < 0.01$ , \*\* $p < 0.01$ , ### $p < 0.001$ ,  
959 \*\*\* $p < 0.001$ .


960

961 **Fig. 8** Evaluation of stress-induced behavior in the brain of wild-type and ob/ob mice. Bar chart showing  
962 the (a) immobility and the (b) mobility latency time percents in Porsolt Swim Test (PST) for last 4 min  
963 of the test. The data are presented as the mean values  $\pm$  standard deviations (SD) of the means. All data  
964 presented representative data obtained from at least three separate experiments. WC, wild-type; WM,  
965 wild-type plus melatonin; ObC, ob/ob; ObM, ob/ob plus melatonin. # wild-type vs. ob/ob and \*

966 melatonin-treated animals vs. untreated animals. # $p < 0.05$ , \* $p < 0.05$ , ## $p < 0.01$ , \*\* $p < 0.01$ , ### $p < 0.001$ ,  
967 \*\*\* $p < 0.001$ .

**Table 1.** Body and tissue parameters: body weight and brain weight at sacrifice.

	<b>WC</b>	<b>WM</b>	<b>ObC</b>	<b>ObM</b>
<b>Body weight at sacrifice (g)</b>	24,19 ± 1,55	24,86 ± 2,08	49,93 ± 5,01 ###	51,48 ± 2,10
<b>Brain weight at sacrifice (g)</b>	0,35 ± 0,02	0,35 ± 0,00	0,31 ± 0,03 ##	0,34 ± 0,03








Figure 3

[Click here to download Figure Fig3.tif](#)

